<DOC>
	<DOCNO>NCT00219388</DOCNO>
	<brief_summary>The purpose study compare effect levosimendan dobutamine heart function patient suffer severe chronic heart failure .</brief_summary>
	<brief_title>Efficacy Safety Treatment With Simdax® Versus Dobutrex® Decompensated Heart Failure Patients .</brief_title>
	<detailed_description>Patients decompensate heart failure ( NYHA III-IV ) need intravenous inotrop support fulfil inclusion exclusion criterion randomise study proportion 1:1 . Although stratification do patient treat beta-receptor blocker carvedilol divide study group . All patient receive infusion parallell , one group receive active product ( levosimendan dobutamine ) receive placebo ( double-dummy technique ) . Catheterisation measurement hemodynamic parameter perform accord routine method clinic . The measurement hemodynamic variable start 30 minute start study drug infusion finish 48 hour start infusion . The important variable measurement Cardiac Index ( CI ) Pulmonary Capillary Wedge Pressure ( PCWP ) . Parallel registration do ECG , blood pressure , blood frequency , central venous pressure , lung artery pressure . Heart failure clinical symptom register continuously 48 hour . Blood sample take intermittent record blood value . Cogent rule decreasing/increasing dose find study protocol , likewise rule interruption stoop infusion . Registration side-effects do continuously . The recommendation treatment know side effect could find protocol ( section 5.3.4 ) protocol available study procedure . One month study patient follow careful examination also amount visit reason visit hospital past 30-35 day .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<mesh_term>Dobutamine</mesh_term>
	<criteria>Main Decompensated chronic heart failure ischemic nonischemic origin , NYHA class III IV , despite optimised conventional treatment may benefit intravenous positive inotropic agent per investigator 's judgment . Ongoing treatment betareceptor block agent stable regimen least 3 month optimal dose per investigator 's judgment . Left ventricular ( LV ) ejection fraction ( EF ) less similar 35 % . CI &lt; 2.5 l/min/m2 . Mean PCWP &gt; 15 mmHg . Main Significant mechanical obstruction affect ventricular fill and/or outflow . Systolic blood pressure 85 mmHg less screen and/or baseline . Heart rate 130 bpm great , persistent least 5 minute screen and/or baseline . Severe angina pectoris 6 hour screen and/or baseline . Deterioration chronic heart failure due acute myocardial infarction within 5 day screen measurement . Administration Simdax within 1 month baseline . A history Torsades de Pointes . Evidence severe renal insufficiency ( serum creatinine &gt; 450 μmol/l dialysis ) screening . Significant hepatic impairment elevation liver enzymes 5 time upper limit normal range analyse laboratory screening . Acute bleed severe anaemia . Heart surgery within 3 month baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Levosimendan</keyword>
	<keyword>Dobutamine</keyword>
	<keyword>Intravenous</keyword>
	<keyword>Invasive hemodynamics</keyword>
	<keyword>Decompensated Heart Failure</keyword>
</DOC>